GOVXHIGH SIGNALOPERATIONAL10-K

GeoVax has completely pivoted its primary strategic focus from COVID-19 vaccines to mpox/smallpox vaccines, abandoning its BARDA-funded lead program GEO-CM04S1.

This represents a fundamental business transformation where the company has shifted from a COVID-19 vaccine developer with active Phase 2 trials and significant BARDA funding to focusing on GEO-MVA for orthopoxviruses. The abandonment of the GEO-CM04S1 program, which had a 10,000-participant Phase 2b trial funded by BARDA and multiple ongoing Phase 2 studies, suggests either significant setbacks in the COVID program or a strategic decision to chase the mpox opportunity following recent outbreaks.

Comparing 2026-04-15 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company burning through cash with a 44% decline in cash reserves to just $3.1M, though this was partially offset by reduced current liabilities and R&D expenses declining 24% to $18.1M. Net losses improved 14% to $21.5M, but with rapidly declining cash and minimal revenue, the company faces significant liquidity challenges especially given the strategic pivot away from its BARDA-funded programs. The combination of deteriorating cash position and abandonment of funded programs raises serious questions about near-term financing needs.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-44%
$5.5M→$3.1M

Cash declined 44% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
-37.7%
$3.1M→$1.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+33.7%
$21K→$28K

Capital expenditure jumped 33.7% — major investment cycle underway; assess returns on deployment.

Current Assets
Balance Sheet
-33%
$7.9M→$5.3M

Current assets declined 33% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
-24.2%
$5.0M→$3.8M

Equity decreased 24.2% — buybacks or losses reducing book value, monitor solvency ratios.

R&D Expense
P&L
-23.6%
$23.7M→$18.1M

R&D spending cut 23.6% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
-22.2%
$8.2M→$6.3M

Total assets contracted 22.2% — asset sales, write-downs, or balance sheet optimization underway.

Total Liabilities
Balance Sheet
-19%
$3.1M→$2.5M

Liabilities reduced 19% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
+14.1%
-$25.0M→-$21.5M

Net income grew 14.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+13.9%
-$25.1M→-$21.6M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-04-15
PRIOR — 2025-03-27
ADDED
( GeoVax , us , we or the Company ) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.
GeoVax s primary near-term strategic development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses.
GEO-MVA is being advanced on an expedited regulatory pathway in Europe and is intended to address a significant global supply constraint for orthopoxvirus vaccines.
The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives.
The advancement of GEO-MVA represents the Company s most near-term opportunity to achieve regulatory approval and potential commercialization.
The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.
A Phase 2 clinical trial evaluating Gedeptin in combination with an immune checkpoint inhibitor (ICI) as first-line treatment of patients with squamous cell head and neck cancer eligible for curative surgery, is planned to initiate during the first half of 2027.
The Company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine which is currently being evaluated in two Phase 2 clinical trials, (i) as a primary vaccine for immunocompromised patients, including those with hematologic cancers and other patient populations for whom currently authorized COVID-19 vaccines are inadequate and (ii) as a booster vaccine in patients with chronic lymphocytic leukemia (CLL), where an interim Data Safety Monitoring Board (DSMB) review demonstrated superior immune responses versus an mRNA vaccine.
An additional clinical trial evaluating GEO-CM04S1 as a more robust booster vaccine in healthy adults who previously received an mRNA vaccine has completed enrollment with data readouts anticipated in the first half of 2026.
Our corporate strategy is to advance, protect, and strategically leverage our proprietary vaccine and immunotherapy platforms to develop differentiated preventive and therapeutic solutions for infectious diseases and solid tumors.
REMOVED
(GeoVax, us, we or the Company) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.
The Company s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax has been awarded a BARDA-funded contract to sponsor a 10,000-participant, randomized, Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus a COVID-19 vaccine approved by the U.S.
The study is anticipated to commence in the second half of 2025.
GEO-CM04S1 is also currently being evaluated in three Phase 2 clinical trials, including: A primary vaccine for immunocompromised patients, such as those with hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are inadequate.
A booster vaccine in patients with chronic lymphocytic leukemia (CLL), which recently demonstrated superior immune responses versus an mRNA vaccine following an interim Data Safety Monitoring Board (DSMB) review.
A more robust booster vaccine among healthy adults who previously received an mRNA vaccine, with data readouts anticipated in mid-2025.
A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin combined with an immune checkpoint inhibitor is planned.
Additionally, the Company is developing GEO-MVA, a vaccine targeting Mpox and smallpox, with clinical evaluation expected to begin in 2025.
GeoVax s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 135 granted or pending patent applications spread over 23 patent families, which are discussed in greater detail in the Our Intellectual Property section.
1 Our Product Development Pipeline The tables below summarize the status of our product development programs, which are discussed in greater detail in the following pages.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →